| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:19Z |
Profile and value of FIB-4 in patients with dual chronic hepatitis C and B
|
Liu C.-J.; Tseng T.-C.; Yang W.-T.; TUNG-HUNG SU; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:19Z |
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection
|
TUNG-HUNG SU; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:18Z |
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma
|
TUNG-HUNG SU; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:17Z |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
|
Liu C.-H.; TUNG-HUNG SU; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
|
Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; TUNG-HUNG SU; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging
|
TUNG-HUNG SU; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourlière M.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:15Z |
Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism
|
TUNG-HUNG SU; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
TUNG-HUNG SU; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; TUNG-HUNG SU; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; TUNG-HUNG SU; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
|
Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:12Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:12Z |
HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis
|
Tseng T.-C.; Liu C.-J.; Chang C.T.; TUNG-HUNG SU; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:11Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-03-09T01:43:11Z |
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer
|
TUNG-HUNG SU; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:10Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
|
Liu C.-H.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:08Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; TUNG-HUNG SU; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-04T07:51:00Z |
Withdrawal period of oxolinic acid in cobia (Rachycentron canadum): Validation of an LC-MS/MS method
|
Chen, R.S.;Sheu, S.Y.;Xue, Y.J.;Wang, C.Y.;Liu, C.H.;Kuo, T.F.;Wang, J.H.;Chou, C.H.; Chen, R.S.; Sheu, S.Y.; Xue, Y.J.; Wang, C.Y.; Liu, C.H.; Kuo, T.F.; Wang, J.H.; Chou, C.H.; CHUNG-HSI CHOU; TZONG-FU KUO |
| 臺大學術典藏 |
2021-03-04T02:36:03Z |
Osteonecrosis of the femoral head in a human immunodeficiency virus type 1-infected patient with lipodystrophy
|
Yu-Chieh Tsai;Liu C.-H.;Liao C.-H.;Chen M.-Y.;Hung C.-C.; YU-CHIEH TSAI; Liu C.-H.; Liao C.-H.; Chen M.-Y.; Hung C.-C. |
| 臺大學術典藏 |
2021-02-26T01:59:37Z |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
|
Liu C.-H.;Wang-Huei Sheng;Sun H.-Y.;Hsieh S.-M.;Lo Y.-C.;Liu C.-J.;Su T.-H.;Yang H.-C.;Liu W.-C.;Chen P.-J.;Chen D.-S.;Hung C.-C.;Kao J.-H.; Liu C.-H.; WANG-HUEI SHENG; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
